However, a number of studies have since examined next‐generation ALK TKIs such as ceritinib, lorlatinib, brigatinib, alectinib and repotrectinib in a preclinical setting, identifying more potent inhibitors for the ALK mutant variants found in NB (Guan et al, 2016; Infarinato et al, 2016; Iyer et al, 2016; Siaw et al, 2016; Guan et al, 2018; Alam et al, 2019; Cervantes‐Madrid et al, 2019). This evidence concerns the gene ALK and neuroblastoma.